

Trypanosoma brucei subsp. gambiense, Strain STIB 386

Catalog No. NR-36198

For research use only. Not for human use.

Contributor:

C. M. R. Turner, Professor of Parasitology, Institute of Infection, Immunology and Inflammation, University of Glasgow, Glasgow, Scotland

Manufacturer:

BEI Resources

Product Description:

Protozoa Classification: Trypanosomatidae, Trypanosoma

Species: Trypanosoma brucei subsp. gambiense

Strain: STIB 386 (also referred to as STIB 386AAA, TH 114/78E(020), and MHOM/CI/78/TH14)¹⁻⁴

Original Source: Trypanosoma brucei (T. brucei) subsp. gambiense, strain STIB 386 was derived from strain TH 114/78E (020), which was isolated in 1978 from a male patient in Koudougou, Ivory Coast, West Africa.^{1,2,4}

Comment: T. brucei subsp. gambiense, strain STIB 386 is identified as a type 2 T. brucei subsp. gambiense with variable expression of human serum resistance⁵. Strain STIB 386 is a parental strain that has been used in a genetic cross with T. brucei subsp. brucei, strain STIB 247 (BEI Resources NR-36197) to generate cloned lines expressing resistance to anti-parasitic drugs and to investigate genetic exchange in a mouse model.^{2,3,6}

T. brucei is a kinetoplastid protozoan parasite and is the causative agent of African trypanosomiasis, which is transmitted to both humans and livestock through the bite of the tsetse fly.^{7,8} The flies inject the infective stage (metacyclic trypomastigotes) from their salivary glands into the blood and lymphatic fluid of the host, where they undergo differentiation and enter the central nervous system by evading the host immune system through the use of antigenic variation of their surface glycoprotein coat.^{7,8}

T. brucei is divided into three morphologically-identical subspecies that demonstrate distinct pathogenicities: T. brucei subsp. gambiense and T. brucei subsp. rhodesiense, which cause African sleeping sickness in humans, and the non-human infective T. brucei subsp. brucei.^{7,9} The production of vaccines against these diseases is difficult as a significant rise of resistance to trypanocidal drugs has been documented. Animal models such as mice are critical to understanding the mechanisms of disease and the development of new therapeutic drugs.⁷

Two types of the human-infective T. brucei subsp. gambiense have been identified, with type 1 characterized as highly-resistant to human serum and type 2 yielding variable

results in the blood incubation infectivity test.¹⁰

Material Provided:

Each vial of NR-36198 contains approximately 0.5 mL of trypanosome infected blood with 20% glycerol, 6.25% Yaeger's anticoagulant and Trypanosome dilution buffer. Please see Appendix I for cryopreservation instructions and component details.

Packaging/Storage:

NR-36198 was packaged aseptically in screw-capped plastic cryovials and is provided frozen on dry ice. The product should be stored at cryogenic temperature (-130°C or colder), preferably in the vapor phase of a liquid nitrogen freezer. If liquid nitrogen storage facilities are not available, frozen cryovials may be stored at -70°C or colder for approximately one week. Note: Do not under any circumstances store vials at temperatures warmer than -70°C. Storage under these conditions will result in the death of the culture.

To insure the highest level of viability, the culture should be initiated immediately upon receipt. Any warming of the product during shipping and transfer must be avoided, as this will adversely affect the viability of the product. For transfer between freezers and for shipping, the product may be placed on dry ice for brief periods, although use of a portable liquid nitrogen carrier is preferred. Please read the following recommendations prior to using this material.

Growth Conditions:

In vivo, Balb/c mouse

Inoculation:

1. Inject one female Balb/c mouse intraperitoneally with cyclophosphamide at a dosage of 150 mg/kg one day before inoculation with T. brucei subsp. gambiense.
2. After 24 hours, thaw a frozen ampule of NR-36197 in a 35°C to 37°C water bath for approximately 2 to 3 minutes.
3. Remove the contents of the ampule using a 1 mL syringe equipped with a 27 gauge 1/2 inch needle.
4. Inject the entire contents of the vial intraperitoneally into the immunosuppressed mouse.

Monitoring parasitemia:

1. Bleed the mouse at 1- to 2-day intervals to monitor parasitemia by microscopic examination using a haemocytometer and 0.85% ammonium chloride as diluent. Parasitemia may also be assessed by microscopic examination of blood films stained with a 5% Giemsa solution.
2. Passage the strain when the infection is at or near the first peak of parasitemia ($\geq 1 \times 10^7$ parasites/mL or ≥ 10 parasites/high power field for Giemsa-stained blood films observed under 100X). This will normally occur after 4 to 5 days of inoculation. Note that the rate of T. brucei subsp. gambiense infection may vary with the parasite strain.

Passaging:

1. Inject approximately 10 female Balb/c mice

intraperitoneally with cyclophosphamide at a dosage of 150 mg/kg one day before inoculation with *T. brucei* subsp. *brucei*.

2. After 24 hours, anesthetize the first infected mouse by CO₂/O₂ inhalation. Collect the blood by orbital bleeding or from the tail vein using an anticoagulant such as Yaeger's anticoagulant solution (Appendix I) or EDTA.
3. Perform a parasite count and inject 5x10⁵ to 1x10⁶ parasites into each of the uninfected mice.
4. Monitor parasitemia as described above and passage as needed.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the BEI Resources, NIAID, NIH: *Trypanosoma brucei* subsp. *gambiense*, Strain STIB 386, NR-36198."

Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI

Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. <http://tryps.rockefeller.edu>
2. Jenni, L., et al. "Hybrid Formation between African Trypanosomes during Cyclical Transmission." Nature. 322 (1986): 173-175. PubMed: 3724860.
3. Turner, et al. "Evidence that the Mechanism of Gene Exchange in *Trypanosoma brucei* Involves Meiosis and Syngamy." Parasitology. 101 (1990): 377-386. PubMed: 1982633.
4. Hide, G., et al. "The Identification of *Trypanosoma brucei* Subspecies using Repetitive DNA Sequences." Mol. Biochem. Parasitol. 39 (1990): 213-225. PubMed: 1969612.
5. Tait, A., et al. "Genetic Analysis of Phenotype in *Trypanosoma brucei* A Classical Approach to Potentially Complex Traits." Philos. Trans. R. Soc. Lond. B. Bio. Sci. 357 (2002): 89-99. PubMed: 11839186.
6. Scott, A. G., et al. "Characterisation of Cloned Lines of *Trypanosoma brucei* Expressing Stable Resistance to MelCy and Suramin." Acta Trop. 60 (1996): 251-262. PubMed: 8659324.
7. Antoine-Moussiaux, N., et al. "Contributions of Experimental Mouse Models to the Understanding of African Trypanosomiasis." Trends Parasitol. 24 (2008): 411-418. PubMed 18684669.
8. Peacock, L., et al. "Identification of the Meiotic Life Cycle Stage of *Trypanosoma brucei* in the Tsetse Fly." Proc. Natl. Acad. Sci. USA 108 (2011): 3671-3676. PubMed: 21321215.
9. Turner, C. M., et al. "Replication, Differentiation, Growth and the Virulence of *Trypanosoma brucei* Infections." Parasitology. 111 (1995): 289-300. PubMed: 7567097.
10. Gibson, W. C. "Will the Real *Trypanosoma b. gambiense* Please Stand Up." Parasitol. Today 2 (1986): 255-257. PubMed: 15462856.

ATCC® is a trademark of the American Type Culture Collection.



APPENDIX I: CRYOPRESERVATION

1. Prepare a 40% (v/v) sterile glycerol solution in Trypanosome dilution buffer (see below).
2. Dispense 0.5 mL of anticoagulant solution (see below) into a 15 mL test tube. Add to the anticoagulant tube blood collected by orbital bleeding from mice that had reached or are near peak parasitemia. Invert the tube several times to mix the blood with the anticoagulant.
3. In a separate test tube, add the heparinized blood dropwise to the 40% glycerol solution. Note that blood should be mixed with glycerol solution in a 1:1 ratio to obtain a final concentration of cryoprotectant of 20% (v/v). Mix slowly by inversion and place the tube on ice. The freezing process should start 15 to 30 minutes following the addition of the heparinized blood to the cryoprotectant solution.
4. Dispense 0.5 mL aliquots of blood suspension into 1 to 2 mL sterile plastic screw-capped cryovials. Place the vials in a controlled rate freezing unit. From room temperature, cool the vials at $-1^{\circ}\text{C}/\text{min}$ to -40°C . If the freezing unit can compensate for the heat of fusion, maintain rate at $-1^{\circ}\text{C}/\text{min}$ through this phase. At -40°C , plunge vials into liquid nitrogen. Alternatively, place the vials in a Nalgene 1°C freezing container. Place the container at -80°C for 1.5 to 2 hours and then plunge vials into liquid nitrogen.
5. To thaw a frozen ampule, place in a 35°C to 37°C water bath, until thawed (2 to 3 min). Immerse the ampule just sufficient to cover the frozen material. Do not agitate the ampule.
6. Immediately after thawing, remove the contents of the ampule aseptically with a syringe and inoculate an immunosuppressed mouse. Follow the protocol for in vivo propagation above.

Trypanosome dilution buffer

20 mM Na_2HPO_4
2 mM NaH_2PO_4
80 mM NaCl
5 mM KCl
1 mM MgSO_4
20 mM Glucose

Adjust the pH of the solution to 7.7 and filter-sterilize.

Yaeger's anticoagulant solution

Sodium citrate	1.33 g
Citric acid	0.47 g
Dextrose	3.00 g
Sodium heparin	0.20 g
Distilled H_2O to	100.0 mL